摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-(chlorosulfonyl)-1-naphthalenecarboxylic acid methyl ester | 141952-09-2

中文名称
——
中文别名
——
英文名称
5-(chlorosulfonyl)-1-naphthalenecarboxylic acid methyl ester
英文别名
Methyl 5-(chlorosulfonyl)naphthalene-1-carboxylate;methyl 5-chlorosulfonylnaphthalene-1-carboxylate
5-(chlorosulfonyl)-1-naphthalenecarboxylic acid methyl ester化学式
CAS
141952-09-2
化学式
C12H9ClO4S
mdl
——
分子量
284.72
InChiKey
CNFVMBKEYPEFQX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3
  • 重原子数:
    18
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.08
  • 拓扑面积:
    68.8
  • 氢给体数:
    0
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    参考文献:
    名称:
    聚乙酰胺模拟物的双重化学修饰:具有强细胞毒性的离子通道形成48-mer肽的合理设计和合成
    摘要:
    Polytheonamide B(1)是一种天然肽,对P388小鼠白血病细胞表现出强大的细胞毒性(IC 50 = 0.098 n m)。已知线性48-mer 1在与脂质双层结合时会形成单价阳离子通道。我们之前开发了1的完全合成路线,然后实现了结构简化的1的类似物的设计和合成,即dansylated polytheonamide mimic 2。尽管发现合成上更容易接近的2模仿了1的通道功能,但其细胞毒性却降低了120倍。本文中,七种类似物的化学制备和生物学评价报告了3 – 9(共2)。化合物3 - 9在它们的N末端和/或残基44的侧链进行了修改2,以改变它们的物理化学性质。的全合成3 - 9是由固相和溶液相化学的组合以统一的方式来完成的。对疏水性,单通道电流,离子交换活性和3 – 9的细胞毒性的系统评价表明,它们的疏水性与离子交换的总强度相关,并确定其细胞毒性潜能。因此,最疏水的类似物9具有最低的IC
    DOI:
    10.1002/chem.201504632
  • 作为产物:
    描述:
    3-[(1-羟基-2-萘基)偶氮]苯磺化钠氯磺酸 作用下, 以4.53 g的产率得到5-(chlorosulfonyl)-1-naphthalenecarboxylic acid methyl ester
    参考文献:
    名称:
    通过核超载增强测量确定取代萘的结构
    摘要:
    通过案例研究描述了方法,该方法结合现代1 H NMR方法确定萘,尤其是萘磺酸衍生物衍生产品中取代基的方向。
    DOI:
    10.1016/s0040-4020(01)88771-8
点击查看最新优质反应信息

文献信息

  • Sulfonamide endothelin antagonists
    申请人:Bristol-Myers Squibb Co.
    公开号:US05378715A1
    公开(公告)日:1995-01-03
    Compounds of the formula ##STR1## inhibit endothelin, wherein: one of X and Y is N and the other is O; R is naphthyl or naphthyl substituted with R.sup.1, R.sup.2 and R.sup.3 ; R.sup.1, R.sup.2 and R.sup.3 are each independently hydrogen; alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, or aralkyl, any of which may be substituted with Z.sup.1, Z.sup.2 and Z.sup.3 ; halo; hydroxyl; cyano; nitro; --C(O)H; --C(O)R.sup.6 ; CO.sub.2 H; --CO.sub.2 R.sup.6 ; --SH; --S(O).sub.n R.sup.6 ; --S(O).sub.m --OH; --S(O).sub.m --OR.sup.6 ; --O--S(O).sub.m --R.sup.6 ; --O--S(O).sub.m OH; --O--S(O).sub.m --OR.sup.6 ; --Z.sup.4 --NR.sup.7 R.sup.8 ; or --Z.sup.4 --N(R.sup.11)--Z.sup.5 --NR.sup.9 R.sup.10 ; R.sup.4 and R.sup.5 are each independently hydrogen; alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, or aralkyl, any of which may be substituted with Z.sup.1, Z.sup.2 and Z.sup.3 ; halo; hydroxyl; cyano; nitro; --C(O)H; --C(O)R.sup.6 ; --CO.sub.2 H; --CO.sub.2 R.sup.6 ; --SH, --S(O).sub.n R.sup.6 ; --S(O).sub.m --OH; --S(O).sub.m --OR.sup.6 ; --O--S(O).sub.m --R.sup.6 ; --O--S(O).sub.m OH; --O--S(O).sub.m --OR.sup.6 ; --Z.sup.4 --NR.sup.7 R.sup.8 ; --Z.sup.4 --N(R.sup.11)--Z.sup.5 --NR.sup.9 R.sup.10 ; or R.sup.4 and R.sup.5 together are alkylene or alkenylene (either of which may be substituted with Z.sup.1, Z.sup.2 and Z.sup.3), completing a 4- to 8-membered saturated, unsaturated or aromatic ring together with the carbon atoms to which they are attached.
    ##STR1##的化合物抑制内皮素,其中:X和Y中的一个是N,另一个是O;R是萘基或被R.sup.1,R.sup.2和R.sup.3取代的萘基;R.sup.1,R.sup.2和R.sup.3分别独立地是氢;烷基,烯基,炔基,烷氧基,环烷基,环烷基烷基,环烯基,环烯基烷基,芳基或芳基烷基,其中任何一个可能被Z.sup.1,Z.sup.2和Z.sup.3取代;卤素;羟基;氰基;硝基;--C(O)H;--C(O)R.sup.6;CO.sub.2 H;--CO.sub.2 R.sup.6;--SH;--S(O).sub.n R.sup.6;--S(O).sub.m --OH;--S(O).sub.m --OR.sup.6;--O--S(O).sub.m --R.sup.6;--O--S(O).sub.m OH;--O--S(O).sub.m --OR.sup.6;--Z.sup.4 --NR.sup.7 R.sup.8;或--Z.sup.4 --N(R.sup.11)--Z.sup.5 --NR.sup.9 R.sup.10;R.sup.4和R.sup.5分别独立地是氢;烷基,烯基,炔基,烷氧基,环烷基,环烷基烷基,环烯基,环烯基烷基,芳基或芳基烷基,其中任何一个可能被Z.sup.1,Z.sup.2和Z.sup.3取代;卤素;羟基;氰基;硝基;--C(O)H;--C(O)R.sup.6;--CO.sub.2 H;--CO.sub.2 R.sup.6;--SH,--S(O).sub.n R.sup.6;--S(O).sub.m --OH;--S(O).sub.m --OR.sup.6;--O--S(O).sub.m --R.sup.6;--O--S(O).sub.m OH;--O--S(O).sub.m --OR.sup.6;--Z.sup.4 --NR.sup.7 R.sup.8;--Z.sup.4 --N(R.sup.11)--Z.sup.5 --NR.sup.9 R.sup.10;或R.sup.4和R.sup.5一起是烷基或烯基(其中任何一个可能被Z.sup.1,Z.sup.2和Z.sup.3取代),与它们连接的碳原子一起形成4-至8-成员饱和,不饱和或芳香环。
  • POLYMER, PHOTOSENSITIVE RESIN COMPOSITION, PATTERNING METHOD, METHOD OF FORMING CURED FILM, INTERLAYER INSULATING FILM, SURFACE PROTECTIVE FILM, AND ELECTRONIC COMPONENT
    申请人:Shin-Etsu Chemical Co., Ltd.
    公开号:EP3896521A1
    公开(公告)日:2021-10-20
    Provided is a polymer that can be used as a base resin for a positive photosensitive resin composition and a negative photosensitive resin composition, wherein the positive photosensitive resin composition and the negative photosensitive resin composition are soluble in an aqueous alkaline solution, can form a fine pattern, can achieve high resolution, and have good mechanical properties even when they are cured at low temperature. Also provided are a positive photosensitive resin composition and a negative photosensitive resin composition using the polymer. The polymer is represented by general formulas (1) and/or (2): wherein T1 and T2 may be the same as, or different from, each other and represent any of -CO- and -SO2-; X1 is a tetravalent organic group; and 1 is 0 or 1; and X2 is a divalent organic group.
    本发明提供了一种聚合物,可用作正感光树脂组合物和负感光树脂组合物的基础树脂,其中正感光树脂组合物和负感光树脂组合物可溶于碱性水溶液,可形成精细图案,可实现高分辨率,即使在低温下固化也具有良好的机械性能。此外,还提供了使用该聚合物的正感光树脂组合物和负感光树脂组合物。该聚合物由通式(1)和/或(2)表示: 其中 T1 和 T2 可以彼此相同或不同,并代表 -CO- 和 -SO2- 中的任何一种;X1 是四价有机基团;1 是 0 或 1;X2 是二价有机基团。
  • Polymer, photosensitive resin composition, patterning method, method of forming cured film, interlayer insulating film, surface protective film, and electronic component
    申请人:International Business Machines Corporation
    公开号:US11333975B2
    公开(公告)日:2022-05-17
    Provided is a polymer that can be used as a base resin for a positive photosensitive resin composition and a negative photosensitive resin composition, wherein the positive photosensitive resin composition and the negative photosensitive resin composition are soluble in an aqueous alkaline solution, can form a fine pattern, can achieve high resolution, and have good mechanical properties even when they are cured at low temperature. Also provided are a positive photosensitive resin composition and a negative photosensitive resin composition using the polymer. The polymer is represented by general formulas (1) and/or (2): wherein T1 and T2 may be the same as, or different from, each other and represent any of —CO— and —SO2—; X1 is a tetravalent organic group; and l is 0 or 1; and X2 is a divalent organic group.
    本发明提供了一种聚合物,可用作正感光树脂组合物和负感光树脂组合物的基础树脂,其中正感光树脂组合物和负感光树脂组合物可溶于碱性水溶液,可形成精细图案,可实现高分辨率,即使在低温下固化也具有良好的机械性能。此外,还提供了使用该聚合物的正感光树脂组合物和负感光树脂组合物。该聚合物由通式(1)和/或(2)表示: 其中 T1 和 T2 可以彼此相同或不同,并代表 -CO- 和 -SO2- 中的任意一种;X1 是四价有机基团;l 是 0 或 1;X2 是二价有机基团。
  • Discovery and Structure-Activity Relationships of Sulfonamide ETA-Selective Antagonists
    作者:Philip D. Stein、David M. Floyd、Sharon Bisaha、Joyce Dickey、Ravindar N. Girotra、Jack Z. Gougoutas、Michael Kozlowski、Ving G. Lee、Eddie C.-K. Liu
    DOI:10.1021/jm00008a013
    日期:1995.4
    Random screening of compounds in an ETA receptor binding assay led to the discovery of a class of benzenesulfonamide ligands. Optimization led to the development of 5-amino-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamides which were functional antagonists. Structural features which were important to activity included a 1,5-substitution pattern on the naphthalene ring; a sulfonamide NH with a pK value < 7; an amine, preferably with alkyl substituents, at the 5-position; and methyl groups on both the 3- and 4-positions of the isoxazole.
  • ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF
    申请人:Enanta Pharmaceuticals, Inc.
    公开号:US20200361920A1
    公开(公告)日:2020-11-19
    The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.
查看更多